Multiparametric MRI is helpful to predict tumor focality, stage, and size in patients diagnosed with unilateral low-risk prostate cancer

To study the staging accuracy of multiparametric magnetic resonance imaging (MRI) in patients showing unilateral low-risk cancer on prostate biopsy. A total of 58 consecutive patients with low-risk cancer (D'Amico classification) and unilateral cancer involvement on prostate biopsies were included prospectively. All patients underwent multiparametric endorectal MRI before radical prostatectomy, including T2-weighted (T2W), diffusion-weighted (DW) and dynamic contrast enhanced (DCE) sequences. Each gland was divided in eight octants. Tumor foci >0.2 cm3 identified on pathological analysis were matched with MRI findings. Pathological examination showed tumor foci >0.2 cm3 in 50/58 glands (86%), and bilateral tumor (pathological stage⩾pT2c) in 20/58 (34%). For tumor detection in the peripheral zone (PZ), T2W+DWI+DCE performed significantly better than T2W+DWI and T2W alone (P<0.001). In the transition zone (TZ), only T2W+DWI performed better than T2W alone (P=0.02). With optimal MR combinations, tumor size was correctly estimated in 77% of tumor foci involving more than one octant. Bilateral tumors were detected in 80% (16/20) of cases. In patients with unilateral low-risk prostate cancer on biopsy, multiparametric MRI can help to predict bilateral involvement. Multiparametric MRI may therefore have a prognostic value and help to determine optimal treatment in such patients.

[1]  Amita Shukla-Dave,et al.  Functional magnetic resonance imaging in prostate cancer. , 2009, European urology.

[2]  N M deSouza,et al.  Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. , 2008, Clinical radiology.

[3]  L. Egevad,et al.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.

[4]  Clare Allen,et al.  Dynamic contrast enhanced MRI in prostate cancer. , 2007, European journal of radiology.

[5]  A. Evans,et al.  Prostate cancer detection with multi‐parametric MRI: Logistic regression analysis of quantitative T2, diffusion‐weighted imaging, and dynamic contrast‐enhanced MRI , 2009, Journal of magnetic resonance imaging : JMRI.

[6]  [Quantitative dynamic MRI and localisation of non-palpable prostate cancer]. , 2009, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[7]  H. Shinmoto,et al.  Prostate cancer screening: The clinical value of diffusion‐weighted imaging and dynamic MR imaging in combination with T2‐weighted imaging , 2007, Journal of magnetic resonance imaging : JMRI.

[8]  Gary Liney,et al.  Correlation of diffusion‐weighted magnetic resonance data with cellularity in prostate cancer , 2009, BJU international.

[9]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[10]  Xavier Leroy,et al.  Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings , 2009, European Radiology.

[11]  Olivier Rouvière,et al.  Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? , 2007, European Radiology.

[12]  Masoom A Haider,et al.  Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. , 2007, AJR. American journal of roentgenology.

[13]  H. Weinmann,et al.  Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. , 1984, Physiological chemistry and physics and medical NMR.

[14]  Rodolfo Montironi,et al.  Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. , 2007, European urology.

[15]  L. Chauveinc,et al.  IRM dynamique quantitative et localisation du cancer de prostate non palpable , 2009 .

[16]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[17]  A S Whittemore,et al.  Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer , 1993, Cancer.

[18]  Silvia D. Chang,et al.  Combined diffusion‐weighted and dynamic contrast‐enhanced MRI for prostate cancer diagnosis—Correlation with biopsy and histopathology , 2006, Journal of magnetic resonance imaging : JMRI.

[19]  A. Renshaw,et al.  Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Sumura,et al.  Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer , 2008, Acta radiologica.

[21]  D. Johnston,et al.  A Streamlined Three-Dimensional Volume Estimation Method Accurately Classifies Prostate Tumors by Volume , 2003, The American journal of surgical pathology.

[22]  A. Tubaro.  Stage migration in clinically localized prostate cancer , 2001 .

[23]  A. Villers,et al.  Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. , 2006, The Journal of urology.

[24]  Theodore L. DeWeese,et al.  Localized Prostate Cancer , 2007 .

[25]  R. Autorino,et al.  Saturation biopsy of the prostate: why saturation does not saturate. , 2009, European urology.

[26]  D. Dearnaley,et al.  A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. , 2009, European urology.